Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease.


Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
10 2021
Historique:
received: 08 07 2020
revised: 18 04 2021
accepted: 11 05 2021
pubmed: 15 6 2021
medline: 8 2 2022
entrez: 14 6 2021
Statut: ppublish

Résumé

The SALVE Histopathology Group (SHG) developed and validated a grading and staging system for the clinical and full histological spectrum of alcohol-related liver disease (ALD) and evaluated its prognostic utility in a multinational cohort of 445 patients. SALVE grade was described by semiquantitative scores for steatosis, activity (hepatocellular injury and lobular neutrophils) and cholestasis. The histological diagnosis of steatohepatitis due to ALD (histological ASH, hASH) was based on the presence of hepatocellular ballooning and lobular neutrophils. Fibrosis staging was adapted from the Clinical Research Network staging system for non-alcoholic fatty liver disease and the Laennec staging system and reflects the pattern and extent of ALD fibrosis. There are 7 SALVE fibrosis stages (SFS) ranging from no fibrosis to severe cirrhosis. Interobserver κ-value for each grading and staging parameter was >0.6. In the whole study cohort, long-term outcome was associated with activity grade and cholestasis, as well as cirrhosis with very broad septa (severe cirrhosis) (p <0.001 for all parameters). In decompensated ALD, adverse short-term outcome was associated with activity grade, hASH and cholestasis (p = 0.038, 0.012 and 0.001, respectively), whereas in compensated ALD, hASH and severe fibrosis/cirrhosis were associated with decompensation-free survival (p = 0.011 and 0.001, respectively). On multivariable analysis, severe cirrhosis emerged as an independent histological predictor of long-term survival in the whole study cohort. Severe cirrhosis and hASH were identified as independent predictors of short-term survival in decompensated ALD, and also as independent predictors of decompensation-free survival in compensated ALD. The SALVE grading and staging system is a reproducible and prognostically relevant method for the histological assessment of disease activity and fibrosis in ALD. Patients with alcohol-related liver disease (ALD) may undergo liver biopsy to assess disease severity. We developed a system to classify ALD under the microscope by grading ALD activity and staging the extent of liver scarring. We validated the prognostic performance of this system in 445 patients from 4 European centers.

Sections du résumé

BACKGROUND & AIMS
The SALVE Histopathology Group (SHG) developed and validated a grading and staging system for the clinical and full histological spectrum of alcohol-related liver disease (ALD) and evaluated its prognostic utility in a multinational cohort of 445 patients.
METHODS
SALVE grade was described by semiquantitative scores for steatosis, activity (hepatocellular injury and lobular neutrophils) and cholestasis. The histological diagnosis of steatohepatitis due to ALD (histological ASH, hASH) was based on the presence of hepatocellular ballooning and lobular neutrophils. Fibrosis staging was adapted from the Clinical Research Network staging system for non-alcoholic fatty liver disease and the Laennec staging system and reflects the pattern and extent of ALD fibrosis. There are 7 SALVE fibrosis stages (SFS) ranging from no fibrosis to severe cirrhosis.
RESULTS
Interobserver κ-value for each grading and staging parameter was >0.6. In the whole study cohort, long-term outcome was associated with activity grade and cholestasis, as well as cirrhosis with very broad septa (severe cirrhosis) (p <0.001 for all parameters). In decompensated ALD, adverse short-term outcome was associated with activity grade, hASH and cholestasis (p = 0.038, 0.012 and 0.001, respectively), whereas in compensated ALD, hASH and severe fibrosis/cirrhosis were associated with decompensation-free survival (p = 0.011 and 0.001, respectively). On multivariable analysis, severe cirrhosis emerged as an independent histological predictor of long-term survival in the whole study cohort. Severe cirrhosis and hASH were identified as independent predictors of short-term survival in decompensated ALD, and also as independent predictors of decompensation-free survival in compensated ALD.
CONCLUSION
The SALVE grading and staging system is a reproducible and prognostically relevant method for the histological assessment of disease activity and fibrosis in ALD.
LAY SUMMARY
Patients with alcohol-related liver disease (ALD) may undergo liver biopsy to assess disease severity. We developed a system to classify ALD under the microscope by grading ALD activity and staging the extent of liver scarring. We validated the prognostic performance of this system in 445 patients from 4 European centers.

Identifiants

pubmed: 34126105
pii: S0168-8278(21)00402-5
doi: 10.1016/j.jhep.2021.05.029
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

810-819

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.

Auteurs

Carolin Lackner (C)

Institute of Pathology, Medical University of Graz, Austria. Electronic address: karoline.lackner@medunigraz.at.

Rudolf E Stauber (RE)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Susan Davies (S)

Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

Helmut Denk (H)

Institute of Pathology, Medical University of Graz, Austria.

Hans Peter Dienes (HP)

Department of Pathology, Medical University of Vienna, Vienna, Austria.

Viviane Gnemmi (V)

Université Lille, Canther, Inserm, UMR-S 1277, CHU Lille, Service de Pathologie, Lille, France.

Maria Guido (M)

Department of Medicine - DIMED, University of Padova, Padova, Italy.

Rosa Miquel (R)

Liver Histopathology Laboratory, Institute of Liver Studies, King's College Hospital, London, United Kingdom.

Valerie Paradis (V)

Assistance Publique-Hôpitaux de Paris, Service d'Anatomie et de Cytologie Pathologiques, Hôpital Universitaire Beaujon, France; Université Paris Diderot, CNRS, Centre de Recherche sur l'Inflammation (CRI), Paris, France; Département Hospitalo-Universitaire (DHU) UNITY, Clichy, France.

Peter Schirmacher (P)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Luigi Terracciano (L)

Anatomic Pathology Institute, Humanitas University Research Hospital, Rozzano, Milano, Italy.

Andrea Berghold (A)

Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.

Gudrun Pregartner (G)

Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.

Lukas Binder (L)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Philipp Douschan (P)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Florian Rainer (F)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Stephan Sygulla (S)

Institute of Pathology, Medical University of Graz, Austria.

Marion Jager (M)

Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.

Pierre-Emmanuel Rautou (PE)

Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.

Andreea Bumbu (A)

Liver Unit, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania; Liver Research Club, Cluj-Napoca, Romania.

Adelina Horhat (A)

Liver Unit, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania; Liver Research Club, Cluj-Napoca, Romania.

Ioana Rusu (I)

University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.

Horia Stefanescu (H)

Liver Unit, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania; Liver Research Club, Cluj-Napoca, Romania.

Sönke Detlefsen (S)

Department of Pathology, Odense University Hospital, Odense C, Denmark; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense C, Denmark.

Aleksander Krag (A)

Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense C, Denmark; Department of Gastroenterology and Hepatology and OPEN, Odense Patient data Explorative Network, Odense University Hospital, Odense C, Denmark.

Maja Thiele (M)

Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense C, Denmark; Department of Gastroenterology and Hepatology and OPEN, Odense Patient data Explorative Network, Odense University Hospital, Odense C, Denmark.

Helena Cortez-Pinto (H)

Clínica Universitária de Gastrenterologia, Laboratório de Nutrição, Faculdade de Medicina, Universidade de Lisboa, Portugal.

Christophe Moreno (C)

Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium.

Annette S H Gouw (ASH)

Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands.

Dina G Tiniakos (DG)

Transitional and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK; Department of Pathology, Aretaieio Hospital, Medical School, National & Kapodistrian University of Athens, Athens 11528, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH